AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
MENLO PARK, Calif. -- Geron Corporation (Nasdaq:GERN) will present an update of the company's product development programs at 8:30 a.m. EST on Wednesday, Nov. 8, 2006, at the Rodman & Renshaw 8th Annual Healthcare Conference in New York City.
The update of Geron's portfolio of telomerase-based anti-cancer therapies will include information about GRN163L and GRNVAC1. The presentation will also include reviews of the company's human embryonic stem cell programs in spinal cord injury (GRNOPC1), heart disease (GRNCM1), and diabetes (GRNIPC1). Thomas B. Okarma, Ph.D., M.D., Geron's president and chief executive officer, ...